

LIST OF MATERIALS CONSIDERED

Description	Exhibit
U.S. Patent No. 8,008,449 B2 (“the ’449 patent”)	1001
U.S. Patent No. 7,595,048 (“the ’048 patent”)	1005
Ishida et al., <i>Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues</i> , Immunology letters 84.1 (2002): 57-62. (“Ishida 1992”)	1006
Iwai et al., <i>Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade</i> , 99(19) Proc. Nat. Acad. Sci. 12293 (2002) (“Iwai 2002”)	1007
Greenwald et al., <i>The B7 family revisited</i> , Annual review of immunology 23 (2005): 515. (“Greenwald 2005”)	1009
Hirano et al., <i>Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity</i> , Cancer research 65.3 (2005): 1089-1096. (“Hirano 2005”)	1010
<i>Bristol-Myers Squibb Company et al v. AstraZeneca Pharmaceuticals LP et al.</i> , C.A. No. 22-cv-00346 (D. Del.), D.I. No. 78-5	1011
PCT Publication No. WO 01/14557 A1 (“WO ’557”)	1012
Stern, M., and R. Herrmann, <i>Overview of monoclonal antibodies in cancer therapy: present and promise</i> , Critical reviews in oncology/hematology 54.1 (2005): 11-29. (“Stern 2005”)	1013
List of approved Antibodies from The Antibody Society	1014
Vaughan et al., <i>Human Antibodies by Design</i> , Nature Biotechnology 16 (1998): 535-539.	1015
Hoogenboom et al., <i>Antibody phage display technology and its applications</i> , Immunotechnology 4 (1998): 1-20. (“Hoogenboom 1998”)	1016
File History For U.S. Patent No. 8,008,449 B2 (“’449 patent File History”)	1017
PCT Publication No. WO 06/121168 A1 (“WO ’168”)	1018
U.S. Provisional Patent Application No. 60/679,466	1019
U.S. Provisional Patent Application No. 60/738,434	1020
U.S. Provisional Patent Application No. 60/748,919	1021
<i>Bristol-Myers Squibb Company et al v. AstraZeneca Pharmaceuticals LP et al.</i> , C.A. No. 22-cv-00346 (D. Del.), D.I. No. 79	1032
PCT Publication No. WO 4/056875 A1 (“WO ’875”)	1033
PCT Publication No. WO 17/011666 A1 (“WO ’666”)	1034

Description	Exhibit
Holm et al., <i>CD4+ CD25+ regulatory T cells: I. Phenotype and physiology</i> , <i>Apmis</i> 112.10 (2004): 629-41. (“Holm 2004”)	1035
Thornton, Angela M., and Ethan M. Shevach, <i>CD4+ CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production</i> , <i>The Journal of experimental medicine</i> 188.2 (1998): 287-296. (“Thornton and Shevach 1998”)	1036
Gavin et al., <i>Homeostasis and anergy of CD4+ CD25+ suppressor T cells in vivo</i> , <i>Nature immunology</i> 3.1 (2002): 33-41. (“Gavin 2001”)	1037
Cai et al., <i>PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells</i> , <i>Cellular immunology</i> 230.2 (2004): 89-98. (“Cai 2004”)	1038
Response to Examination report, dated April 4, 2012, in European Patent Application No. 09013687.0-2405	1039
Daugherty, Ann L., and Randall J. Mersny, <i>Formulation and delivery issues for monoclonal antibody therapeutics</i> , <i>Advanced drug delivery reviews</i> 58.5-6 (2006): 686-706. (“Daugherty 2006”)	1040
Bindon et al., <i>Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q</i> , <i>The Journal of experimental medicine</i> 168.1 (1988): 127-142. (“Bindon 1988”)	1041
Conrath et al., <i>Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs</i> , <i>Journal of Biological Chemistry</i> 276.10 (2001): 7346-7350. (“Conrath 2001”)	1042
Lindhofer et al., <i>Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models</i> , (1996): 4651-4658. (“Lindhofer 1996”)	1043
Maynard, Jennifer, and George Georgiou, <i>Antibody engineering</i> , <i>Annual review of biomedical engineering</i> 2.1 (2000): 339-376. (“Maynard 2000”)	1044
Zurawski et al., <i>The Primary Binding Subunit of the Human Interleukin-4 Receptor Is Also a Component of the Interleukin-13 Receptor</i> , <i>Journal of Biological Chemistry</i> 270.23 (1995): 13869-13878. (“Zurawski 1995”)	1045
Parks et al., <i>Flow cytometry and fluorescence-activated cell sorting</i> , <i>Fundamental immunology</i> 781 (1989). (“Parks 1989”)	1046

Description	Exhibit
PÉREZ, De La Lastra, and B. E. R. G. Van Den, <i>Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP)</i> , Immunology 96.4 (1999): 663-670. (“Perez 1999”)	1047
Tosi et al., <i>Quantitative immunofluorescent assay of full-length, recombinant CD4 in solution and mapping of its epitopes</i> , Journal of Fluorescence 1.2 (1991): 141-146. (“Tosi 1991”)	1048
Sims et al., <i>Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex</i> , Journal of Biological Chemistry 266.12 (1991): 7345-7352. (“Sims 1991”)	1049
Product information for Anti-Human PDCD1 Recombinant Antibody (PD1-17) (CAT#: TAB-0961CL) available at https://www.creativebiolabs.net/Anti-PDCD1-Therapeutic-Antibody-27649.htm	1050
Product Information for Anti-PD-1 [PD1-28], Human IgG1, Lambda Absolute Antibody (PD1-28) (Product #: Ab02652-10.0) available at https://absoluteantibody.com/product/anti-pd-1-pd1-28	1051
Flamar et al., <i>Non-covalent Assembly of Anti-Dendritic Cell Antibodies and Antigens for Evoking Immune Responses in vitro and in vivo</i> , Journal of Immunology 189(5) (2012): 2645-2655.	1052
Product information for Q15116 PDCD1_HUMAN available at https://www.uniprot.org/uniprotkb/Q15116/entry	1053
Product information for CHOgro® High Yield Expression System available at https://www.mirusbio.com/products/transfection/chogro-high-yield-expression-system	1054
Product information for Fluorescent Protein Labeling Kits available at https://www.thermofisher.com/order/catalog/product/A20173	1055
Vaswani, et al., Humanized antibodies as potential therapeutic drugs, Annals of Allergy, Asthma, & Immunology, Volume 81 (1998); 105-119.	1056
GenBank® Accession No. BC074740.2, GI No. 50960296, "Homo sapiens programmed cell death 1, mRNA (cDNA clone MGC:103817 Image:30915198), complete cds	1057
U.S. Patent No. 9,580,505 (“the ’505 patent”)	1058
U.S. Patent No. 9,580,507 (“the ’507 patent”)	1059
Staerz et al., <i>Hybrid antibodies can target sites for attack by T cells</i> , Nature 314 (1985) 628-631	1060

Description	Exhibit
Perez et al., <i>Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody</i> , Nature 316 (1985) 354-356	1061
Staerz and Bevan, <i>Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity</i> , Proc. Natl. Acad. Sci. USA 83 (1986), 1453-57	1062
Staerz and Bevan, <i>Use of anti-receptor antibodies to focus T-Cell activity</i> , Immunology Today 7 (1986) 241-245	1063
Vector information for pIRES2 DsRed-Express2 Vector	1068
Janeway CA Jr et al. <i>Immunobiology: The Immune System in Health and Disease</i> . 5th edition. New York: Garland Science; 2001. The structure of a typical antibody molecule. Available at https://www.ncbi.nlm.nih.gov/books/NBK27144/ (“Janeway 2001”)	1069
Wang et al., <i>In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates</i> , Cancer Imm Res, 2(9): (2014) 846-56 (“Wang 2014”)	1070
Any other materials cited or referenced in my declaration	N/A